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Abstract
Fluorescein-di-b-D-galactopyranoside (FDG), a fluorogenic compound, is hydrolyzed by b-galactosidase in the cytoplasm of
Escherichia coli to produce a fluorescent dye, fluorescein. We found that both FDG and fluorescein were substrates of efflux
pumps, and have developed a new method to evaluate efflux-inhibitory activities in E. coli using FDG and a microfluidic
channel device. We used E. coli MG1655 wild-type, DacrB (DB), DtolC (DC) and DacrBDtolC (DBC) harboring plasmids carrying
the mexAB-oprM (pABM) or mexXY-oprM (pXYM) genes of Pseudomonas aeruginosa. Two inhibitors, MexB-specific
pyridopyrimidine (D13-9001) and non-specific Phe-Arg-b-naphthylamide (PAbN) were evaluated. The effects of inhibitors on
pumps were observed using the microfluidic channel device under a fluorescence microscope. AcrAB-TolC and analogous
pumps effectively prevented FDG influx in wild-type cells, resulting in no fluorescence. In contrast, DBo rDC easily imported
and hydrolyzed FDG to fluorescein, which was exported by residual pumps in DB. Consequently, fluorescent medium in DB
and fluorescent cells of DC and DBC were observed in the microfluidic channels. D13-9001 substantially increased
fluorescent cell number in DBC/pABM but not in DBC/pXYM. PAbN increased medium fluorescence in all strains, especially
in the pump deletion mutants, and caused fluorescein accumulation to disappear in DC. The checkerboard method revealed
that D13-9001 acts synergistically with aztreonam, ciprofloxacin, and erythromycin only against the MexAB-OprM producer
(DBC/pABM), and PAbN acts synergistically, especially with erythromycin, in all strains including the pump deletion mutants.
The results obtained from PAbN were similar to the results from membrane permeabilizer, polymyxin B or polymyxin B
nonapeptide by concentration. The new method clarified that D13-9001 specifically inhibited MexAB-OprM in contrast to
PAbN, which appeared to be a substrate of the pumps and permeabilized the membranes in E. coli.
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Introduction
Increasing multidrug resistance in clinical isolates is currently a
major problem in infection control. In particular, the resistance of
multidrug resistant Pseudomonas aeruginosa (MDRP) to major
antipseudomonal agents, such as carbapenems, quinolones, and
aminoglycosides [1,2], has been demonstrated and is known to
cause nosocomial outbreaks in Japan [3,4]. P. aeruginosa has natural
intrinsic resistance tendencies, and MDRPs have complex
resistance mechanisms [5,6]. In particular, multidrug efflux
pumps, especially resistance-nodulation-cell division (RND) family
pumps, can decrease the sensitivity of P. aeruginosa to various types
of compounds [7,8]. Twelve intrinsic efflux systems belonging to
the RND family have been characterized from the genome
sequence of P. aeruginosa [9], and in particular MexAB-OprM,
MexCD-OprJ, MexEF-OprN and MexXY efflux systems are
known to have important roles in multidrug resistance
[6,10,11,12]. These systems can increase their resistance levels
by acquiring additional resistance factors [13,14]. During this
period of new antibacterial agent scarcity, RND pump inhibitors
appear useful for treating MDRP infections. The enhancing effects
of an experimentally available efflux pump inhibitor, Phe-Arg-b-
naphthylamide (PAbN, MC-207,110) [15], on antibacterial
activities of compounds in combination with several antibiotics
have been published [12,15,16], although no clinically useful
inhibitor is known. Recently, 3D structures of MexB [17] and co-
crystal structures of AcrB with various substrates have been
resolved [18], and some information regarding their mechanisms
of efflux is available. At present, rational approaches are being
employed to develop potent efflux pump inhibitors. However, no
satisfactory method to determine the efflux inhibitory activities of
candidate compounds directly is available.
Fluorescein-di-b-D-galactopyranoside (FDG, Figure 1) is a
fluorogenic compound that is non-fluorescent until it is hydrolyzed
by b-galactosidase in the cytoplasm of Escherichia coli to produce a
highly fluorescent dye, fluorescein [19,20,21]. We first confirmed
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e18547that both FDG and fluorescein are substrates of RND pumps in E.
coli. In addition, recent progress in microfabrication technologies
including soft lithography [22] has expanded their application in
biology [19,23,24]. In this study, we constructed a simple
microfluidic channel device for bacteria. By combining FDG
and the microfluidic device, we developed a novel and highly
sensitive method to evaluate the efflux inhibitory activities of
compounds against P. aeruginosa MexB and MexY in E. coli, and
clarified difference of action mechanism between two inhibitors,
pyridopyrimidine (D13-9001) [25] and PAbN (Figure 1).
Materials and Methods
Bacterial strains and plasmids
Table 1 lists all strains and plasmids used in the present study. E.
coli MG1655 (wild-type), and its deletion mutants—DacrB (DB),
DtolC (DC), and DacrBDtolC (DBC) [26]—were used. The vector
plasmid pMMB67HE recombined with efflux pump genes mexAB-
oprM and mexXY-oprM from P. aeruginosa [27] were kindly provided
by Dr. Taiji Nakae. These plasmids were transformed with DBC
to construct DBC/pMMB67HE (DBC/pV), DBC/pMMB67HE::-
mexAB-oprM (DBC/pABM), and DBC/pMMB67HE::mexXY-oprM
(DBC/pXYM). MDRP IMCJ2.S1 (S1) [28] was kindly provided
by Dr. Kirikae. P. aeruginosa PAO1 was the standard strain.
Antibacterial agents and chemicals
Antibacterials used were aztreonam (ATM; Sigma-Aldrich,
Tokyo, Japan), ciprofloxacin (CIP; Tokyo Chemical Industry co.,
Ltd., Tokyo, Japan), erythromycin (ERY; Nacalai Tesque, Inc.,
Kyoto, Japan), and polymyxin B (PMB; MERCK KGaA,
Darmstadt, Germany). D13-9001 (Daiichi Sankyo Co., Tokyo,
Japan; Figure 1) and PAbN (Sigma-Aldrich; Figure 1) were used as
efflux pump inhibitors. Polymyxin B nonapeptide (PMBN; Sigma-
Aldrich) was used as an outer membrane permeabilizer. Ampicillin
(AMP; Sigma-Aldrich) was added to cultures to ensure retention of
the plasmid. Lactose (Sigma-Aldrich) or isopropyl-b-D-galactopyr-
anoside (IPTG; Sigma-Aldrich) was added to the medium for b-
galactosidase and plasmid-mediated pump induction. FDG
(Marker Gene Technologies, Inc., Eugene, USA; Figure 1) and
SYTOX Green (Lonza Walkersville, Inc., USA) were used for
fluorometry. Nitrocefin (CalBiochem, San Diego, USA) was used
as a substrate of b-lactamase in nitrocefin permeabilizing assay.
Preparation of microfluidic channels
Microfluidic channels (100 mm in width, 17 mm in height, 25–
33 mm in length; Figure 2A) fabricated in polydimethylsiloxane
(PDMS; Silpot 184, Dow Corning Toray Co., Ltd., Tokyo, Japan)
on a cover glass (Matsunami Glass Ind., Ltd., Osaka, Japan) were
prepared as follows [22]. The pattern of each channel was
designed by a software (Illustrator, Adobe Systems Incorporated,
San Jose, USA), and the photomask was prepared by projecting
the designed image (demagnified610) on a 2.5-inches square glass
plate (High precision photo plate PXJP, Konica-Minolta Holdings
Inc., Tokyo, Japan). A photoresist (SU8-25, MicroChem, Newton,
USA) was spin-coated on a silicon wafer (76 mm in diameter,
Ferrotec Co., Tokyo, Japan) at 2000 rpm for 30 s and pre-baked
at 65uC for 3 min and 95uC for 3 min on a hot plate (MH-180CS,
AS ONE Co., Osaka, Japan). The photoresist was then covered
with the photomask and exposed to UV light for 11 s using a mask
aligner (ES20, Nanomeric Technology Inc., Tokyo, Japan). The
photoresist was baked at 65uC for 1 min and at 95uC for 3 min,
after which it was developed for 5 min, and was subsequently
hard-baked at 180uC for 1 h. A patterned photoresist was spin-
coated with a hydrophobic polymer (0.84% CYTOP, Asahi Glass
Figure 1. Chemical structures of fluorescein-di-b-D-galactopyranoside (FDG), fluorescein, and inhibitors.
doi:10.1371/journal.pone.0018547.g001
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1 h, and used as a mould for the channel. PDMS and a catalyst,
mixed (10:1 by weight) and degassed under vacuum for 30 min,
were put in the mould and cured at 100uC for 30 min.
Polymerised PDMS peeled off the mould and the cover glass
pre-cleaned with ethanol were treated with oxygen plasma using a
reactive ion etching instrument (RIE-10NR, Samco, Kyoto,
Japan) under appropriate conditions (Oxygen flow: 100 cc/min;
Pressure: 50 Pa; RF power: 30 W) for 20 s and then bonded to
each other. The inlet and outlet of the channel were then punched
(BP-15F, Kai Industries Co., Ltd., Seki, Japan).
Determination of MICs and checkerboard MICs
MICs of the antibacterial agentsand checkerboardMICs of these
in combination with the inhibitors or the membrane permeabilizer
were determined using the microdilution method defined by
the Clinical and Laboratory Standards Institute (CLSI; Wayne,
PA, USA). Strains harboring the plasmid were cultured in a
medium containing 100 mg/ml AMP and 1 mM IPTG. The best
fractional inhibitory concentration (FIC) indices were calculated as
[MICA in combination/MICA alone+MICB in combination/MICBa l o n ]
Synergy was defined as an FIC index of less than 0.5.
Efflux pump inhibition assay (FDG assay)
Effects of inhibitors on FDG and fluorescein efflux were
observed in the microfluidic channel with a BZ-8000 fluorescence
microscope (KEYENCE, Osaka, Japan). Overnight cultures of the
strains in Luria–Bertani broth (LB; Becton Dickinson and
Company, Sparks, USA) were inoculated in fresh broth and
Table 1. Bacterial strains and plasmids.
Abbreviation
Strain
or plasmid
Source or
reference
Strain Wild Escherichia
coli MG1655
[26]
DB MG1655 DacrB [26]
DC MG1655 DtolC [26]
DBC MG1655 DacrBDtolC [26]
DBC/pV MG1655
DacrBDtolC
/pMMB67HE
This study
DBC/pABM MG1655
DacrBDtolC/
pMMB67HE::
mexAB-oprM
This study
DBC/pXYM MG1655 DacrB
DtolC/pMMB67HE
::mexXY-oprM
This study
PAO1 Pseudomonas
aeruginosa PAO1
S1 Pseudomonas
aeruginosa IMCJ2.S1
[28]
Plasmid pV pMMB67HE [27]
pABM pMMB67HE::mexAB-oprM [27]
pXYM pMMB67HE::mexXY-oprM [27]
doi:10.1371/journal.pone.0018547.t001
Figure 2. The microfluidic device and principle of the efflux pump inhibition assay used in this study. (A) Images of the microfluidic
device used in this study. (B) An example of the assay: Bright-field (top) and fluorescence images (bottom) of the E. coli wild-type, DB and DC cells.
The 8-bit gray-scale fluorescence image was displayed using a pseudo-color (black/green). (C) Mechanism of the efflux pump inhibition assay with
FDG as a substrate. (D) Distributions of fluorescence intensities of the cells and channels measured in the image shown in (B).
doi:10.1371/journal.pone.0018547.g002
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0.8. Lactose (50 mM) was added to induce b-galactosidase in
strains harboring no plasmid. LB containing 100 mg/ml AMP and
1 mM IPTG was used to grow strains harboring the plasmid. The
cultures were premixed with an inhibitor, injected in the
microfluidic channels (Figure 2A) with 100 mg/ml FDG, and
observed under a microscope after incubation for 15 min at 37uC.
Multiple channels containing different samples were observed
simultaneously in a single image field (Figure 2B). The 8-bit gray-
scale fluorescence (Figure 2B, bottom) and bright-field (Figure 2B,
top) images were sequentially obtained with a cooled CCD
camera. Individual cells, most of them are single, adhered to the
surface and were immobile in microchannel, were identified by
eye and the position of them in fluorescence image was determined
manually from the bright-field image. Although it was difficult to
discriminate between the intracellular and extracellular fluores-
cence intensity in the presence of high external fluorescein
background due to the limited lateral and longitudinal resolutions
of the optical microscope, we were able to correctly determine the
position of the cell in the fluorescence image with this procedure.
Fluorescence intensity of the individual cells and channels next to
the cells were measured using ImageJ software (Figure 2D). The
assays were carried out at least two times for individual
experimental conditions, and 30–60 cells were analyzed in each
experimental condition in a single assay.
Nitrocefin hydrolysis assay
The wild-type and DC strains harbouring plasmid pMMB67HE
were constructed and used for the assay. The exponentially
growing cultures (OD600 0.6,0.7) of these strains in LB containing
100 mg/ml of AMP were harvested, and resuspended in AMP-free
LB. Nitrocefin was added to the cell suspension to give a final
concentration of 50 mg/ml, after 10 min incubation with serial
concentrations of PAbN. Hydrolysis of nitrocefin was monitored in
a 384-well plate with a SH-8100 microplate reader (Corona
Electric Co., Ltd, Hitachinaka, Japan) at 486 nm.
SYTOX Green uptake assay
Exponentially growing (OD600=0.7–1.0) wild-type, DB, and
DC cells harvested in PBS containing 0.4% glucose were used.
SYTOX Green is a high-affinity nucleic acid stain that easily
penetrates cells with compromised membranes, but does not
penetrate cells with intact membranes. Membrane integrity was
determined after exposure to D13-9001, PAbN, and PMB for
20 min by measuring the uptake of SYTOX Green. Fluorescence
was determined (Ex/Em: 504/523 nm) after a 10-min incubation
with SYTOX Green in a black 384-well plate with the SH-8100
microplate reader.
Results
MICs of antimicrobial agents against tested strains
Table 2 shows MICs of agents against strains of E. coli and P.
aeruginosa used in this study. PAbN had weak antibacterial activity
against these E. coli and P. aeruginosa strains, and its MIC changed
by deletion or introduction of the pump genes, which revealed that
pump deletion mutants had higher sensitivity to PAbN than the
wild-type strain. The results indicate that PAbN is a substrate of
RND pumps. D13-9001 had no antibacterial activity against these
strains at concentrations less than 64 mg/ml. MIC of ATM against
E. coli was not influenced by acrB and tolC deletion or pXYM
introduction. However, pABM introduction decreased the sensi-
tivity of DBC to ATM by 8-fold. In contrast, MICs of CIP and
ERY against E. coli were decreased by acrB and/or tolC deletion
and increased by pABM and pXYM introduction. MICs of PMB
and PMBN were not influenced by deletion or introduction of
these pump genes.
Combinatorial effects of inhibitors and antibacterial
agents in the checkerboard method
We used three different types of antimicrobial agents to evaluate
combinatorial effects of inhibitors. ATM is a substrate of MexB,
although CIP and ERY are substrates of several pumps. CIP easily
penetrates outer membranes of Gram-negative bacteria, but ERY
hardly penetrates them [29]. Changes in MIC depending on
increased concentrations of inhibitors are shown by each
combination of inhibitor and antimicrobial agent. First, the effect
of inhibitors on the susceptibilities of E. coli MG1655 and its pump
deletion mutants, DB and DC, were compared (Figure 3). D13-
9001 acted synergistically with CIP and/or ERY against the wild-
type strain and had no effect with either agent against DB and DC
(Figure 3A, B). On the other hand, PAbN increased ERY activity
against all strains including DB and DC (Figure 3D). The lowest
FIC index was 0.094 for the wild-type strain and 0.188 for both
mutants. In contrast, the effect of PAbN on CIP activity was only
additive (FIC index=0.75–1) against these strains (Figure 3C).
Subsequently, the effects of inhibitors on P. aeruginosa and E. coli
expressing pumps from P. aeruginosa were examined (Figure 4).
D13-9001 acted synergistically with ATM and CIP but not with
ERY, which has a higher affinity for MexY than MexB (Table 2),
against both sensitive and resistant P. aeruginosa, and the synergy
between D13-9001 and ATM, which has affinity for MexB but not
for MexY, was remarkable in these strains (Figure 4A–C). In E.
coli, D13-9001 increased the susceptibilities of DBC/pABM to all
three agents and had no effect on the susceptibilities of DBC/pV
and DBC/pXYM (Figure 4A–C). The lowest FIC indices of PAbN
with ATM, CIP, and ERY obtained against MDRP S1
(Figure 4D–F) were 0.188, 0.063, and 0.05, respectively. PAbN
again acted synergistically with ERY against all strains including
DBC/pV. The effect of PAbN was weak on PAO1 with ATM or
CIP. Furthermore, the effect of PAbN on CIP activity was not
synergistic against all these E. coli strains. PAbN acted synergis-
tically with ATM in DBC/pXYM and DBC/pV, although it was
additive in DBC/pABM. Synergy between PAbN and these
antimicrobial agents was not explainable by efflux pump inhibition
by PAbN.
Table 2. MICs of antimicrobial agents against tested strains.
Agents MIC; mg/ml
E. coli P. aeruginosa
Wild DB DC
DBC
/pV
DBC/
pABM
DBC
/pXYM PAO1 S1
D13-9001 .64 .64 .64 .64 .64 .64 .64 .64
PAbN 256 64 64 32 256 128 512 512
ATM 0.125 0.063 0.125 0.125 1 0.125 2 64
CIP 0.016 0.004 0.002 0.002 0.016 0.031 0.063 32
ERY 32 2 1 1 16 32 256 256
PMB 2 2 2 2 2 2 2 2
PMBN 64 64 64 .8 .8 .8 .8 .8
D13-9001, pyridopyrimidine; PAbN, Phe-Arg-b-naphthylamide; ATM, aztreonam;
CIP, ciprofloxacin; ERY, erythromycin; PMB, polymyxin B; PMBN, polymyxin B
nonapeptide.
doi:10.1371/journal.pone.0018547.t002
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assay
At the beginning of development of the FDG assay, we
confirmed that induced activities of b-galactosidase in strains used
in this study were comparable after acrB and/or tolC deletion and
introduction of pumps from P. aeruginosa by a plasmid. AcrAB-
TolC and the analogous RND pumps effectively prevented FDG
influx in E. coli wild-type cells, resulting in no fluorescence
(Figure 2B, C-1). In contrast, DB and DC easily infiltrated and
hydrolyzed FDG to fluorescein, which accumulated in DC cells
but not in DB cells. Consequently, we observed fluorescent
medium in DB (Figure 2B, C-2) and fluorescent cells in DC
(Figure 2B, C-3). Images of these strains in the microfluidic
channels are shown in Figure 2B. Fluorescence intensity of each
cell identified in a bright-field image was determined and plotted
in Figure 2D. Fluorescence distributions of the wild-type, DB, and
DC strains were isolated from each other, and fluorescence was
highly accumulated only in DC.
The effect of D13-9001 was not significant in wild-type E. coli in
the new method (Figure 5). Fluorescence in the device decreased to
a minor extent by D13-9001 in a concentration-dependent
manner in DB and DC, and the possibility of FDG blocking
activity of D13-9001 was suggested. On the other hand, PAbN
increased fluorescence in the medium of all strains, especially in
DC, and accumulation of fluorescein in the cells of DC
disappeared (Figure 6).
We also evaluated the inhibitors in relation to the MexAB-
OprM and MexXY-OprM pumps from P. aeruginosa in E. coli. The
fluorescent medium was observed in DBC carrying pABM or
pXYM, while fluorescent cells were observed in DBC/pV
(Figure 7), so these RND pumps from P. aeruginosa appeared to
be working in E. coli DBC. D13-9001 clearly increased the
accumulation of fluorescein in DBC/pABM cells, and fluorescent
cells increased by D13-9001 in a concentration-dependent manner
in DBC/pABM, although it had almost no effect on DBC/pXYM.
PAbN also increased fluorescence in the medium of all these
strains (data not shown).
Characterization of PAbN activity on membrane in
comparison with an outer membrane permeabilizer
PMBN
By the new method, PAbN seemed to have membrane
peameabilizing activity. Separately from efflux pump inhibitor,
even old, outer membrane permeabilizer has been approached to
enhance activity of antimicrobial agents [30,31,32,33]. Among
them, PMBN is known to peameabilize outer membrane but inner
membrane of Gram-negative bacteria, although PMB peameabi-
lizes both membranes [34,35,36]. We determined activity of
PMBN in combination with CIP or ERY (Figure 8). Effect of
PMBN on CIP activity was additive against the E. coli strains and
PAO1, and was synergistic against S1. In contrast, PMBN
increased ERY activity against all strains including DB, DC and
DBC/pV. These results obtained from PMBN were comparable
with the results from PAbN. Effect of PMB on ERY was additive
against all strains tested (Data not shown).
We further evaluated membrane peameabilizing activity of
PAbN with PMB and PMBN in DC by the new device method
(Figure 6, Figure 9). Fluorescein accumulation in DC cells was
disappeared by 4 mg/ml of PAbN as well as by PMBN. PMB
increased fluorescence of medium in more than 1 mg/ml, and
fluorescein accumulation was still seen in 1 mg/ml of PMB. MexB
inhibitor D13-9001 had almost no effect on fluorescein distribu-
tion in DC (Figure 5). Disappeared accumulation of fluorescein in
DC cells and increased fluorescence in the medium of DC would
correspond with peameabilizing of outer membrane and inner
membrane of E. coli, respectively. The effect of PAbN was similar
with PMBN in lower concentrations, and was similar with PMB in
higher concentrations (Figure 6). Effect of outer membrane
permeabilizer is significant with antibacterial agents that are
effectively excluded by the intact outer membrane. Synergistic
action of PAbN in combination with ERY seemed come from its
outer membrane peameabilizing activity.
Outer Membrane permeabilization determined by
nitrocefin hydrolysis assay
Nitrocefin, a chromogenic b-lactam is easily hydrolyzed by
periplasmic b-lactamase of cells having permeabilized outer
membrane, so that its increased rate of hydrolysis in intact cells
has been used for an indicator of increased outer membrane
permeation of nitrocefin [37]. We used both wild-type and DC
strains harbouring plasmid pMMB67HE for the nitrocefin assay,
Figure 3. Effects of D13-9001 and PAbN on CIP and ERY
activity. E. coli MG1655 and its pump deletion mutants were used.
Changes in CIP and ERY MICs induced by D13-9001 or PAbN were
determined by the checkerboard method.
doi:10.1371/journal.pone.0018547.g003
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(Figure 10). Ten minutes incubation with PAbN in the
concentration higher than 4 mg/ml increased nitrocefin hydrolysis
in the both strains. Activity of efflux pumps in the wild-type strain
had almost no effect on nitrocefin assay, although MexAB-OprM
overproduction in P. aeruginosa diminished the effect of PAbNo n
nitrocefin hydrolysis in the literature of Lomovskaya et al. [15].
The results show stronger activity of PAbN on outer membrane of
E. coli than on that of P. aeruginosa published in the past [15]. Outer
membrane permeabilizing activity of PAbN in this nitrocefin
hydrolysis assay was harmonized with the activity obtained from
the FDG assay.
Inner Membrane permeabilization determined by SYTOX
Green uptake assay
SYTOX Green, a DNA intercalater, barely penetrates
membranes of intact cells. In the three E. coli strains tested,
determined fluorescence was slightly higher in pump deletion
mutants than in the wild-type strain (Figure 11). The membrane
permeabilizer PMB increased SYTOX Green uptake in all strains,
regardless of efflux pump activity. PAbN increased SYTOX
Green uptake in these strains, although its effect was moderate in
the wild-type cells and remarkable in the DB and DC cells. MICs
of PAbN (Table 2) correlated with its inner membrane-damaging
activity obtained in Figure 11, which appeared to be the
mechanism of its antibacterial action. D13-9001 slightly decreased
SYTOX Green uptake in all of the strains as well as the results
obtained from FDG uptake in the new method.
Discussion
Several fluorometric methods evaluating efflux pump inhibitors
have been published using substrates of these pumps such as
alanine b-naphthylamide [15], N-phenylnaphthylamine [15],
ethidium bromide [15], and pyronin Y [39]. Lomovskaya et al.
used a related compound MC-002,595 instead of PAbN in the
methods using alanine b-naphthylamide or N-phenylnaphthyla-
mine. They could not determine inhibitory activities of PAbN itself
by these methods due to the high background fluorescence [15].
Figure 4. Effect of D13-9001 and PAbN on ATM, CIP, and ERY activity. E. coli MG1655 DBC expressing MexAB-OprM or MexXY-OprM, and P.
aeruginosa PAO1 and S1 were used. Changes in ATM, CIP, and ERY MICs induced by D13-9001 or PAbN were determined by the checkerboard
method.
doi:10.1371/journal.pone.0018547.g004
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on efflux of ethidium bromide [15,40,41], which is also known as a
substrate of ABC-type transporter [42]. What is more, fluores-
cence of these compounds was not as strong as that of fluorescein,
and thus they are not considered to be suitable for the assay in the
microfluidic channel. The role of efflux pumps on FDG hydrolysis
in E. coli was not fully understood when we chose FDG as a
substrate for the assay at the beginning of this study. FDG was
defined as a substrate of RND pumps because it was easily
hydrolyzed in pump deletion mutants compared with wild-type
cells (Figure 2). If FDG was not a substrate of pumps, it will be
difficult to discriminate DB from wild-type. Fluorescein was also
defined as a substrate of pumps from its accumulation in DC cells.
Furthermore, from the results of complete blockage of FDG
hydrolysis by protonophore CCCP addition in all of the strains
including DC (data not shown), FDG was defined to be actively
imported into the cytoplasm. The lactose permease LacY is not a
FDG permease because lacY deletion from DlacI mutants
(constitutive b-galactosidase producer) had no effect on FDG
hydrolysis in the mutants (data not shown), and we have yet to
identify a FDG permease. Figure 12 shows the proposed
mechanism of FDG hydrolysis in E. coli. In wild-type cells, FDG
is hardly imported into cytoplasm because FDG is exported by
AcrB from periplasm before it is trapped by permease. Rate of
FDG influx will increase depending on a concentration of FDG in
periplasm until it reach maximum rate. Moderate inhibition of the
pumps causes FDG influx and an efflux of fluorescein from the
cells by the remaining activity of the pumps, and full inhibition of
Figure 5. Effects of D13-9001 on FDG degradation determined by the microfluidic channel device. (A) Bright-field (top) and fluorescence
images (bottom) of the E. coli wild-type, DB, and DC cells treated with different concentrations of PP. (B) Distributions of the fluorescence intensities
of the cells and channels measured in the image shown in (A).
doi:10.1371/journal.pone.0018547.g005
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what is observed in DC cells (Figure 2). A real pump inhibitor
without any effect on bacterial membrane will increase fluores-
cence in wild-type cell by concentration dependent manner and
will cause increased accumulation of fluorescence in the cells. In
fact, we detected moderately increasing fluorescence and increased
accumulation of fluorescence in DBC/pABM according to
increasing concentration of D13-9001 (Figure 6). In contrast,
peameabilization of outer membrane will cause leakage of
fluorescein from DC cells, and peameabilization of inner
membrane will efficiently increase FDG influx and fluorescein
production to release it from cells with or without pumps. By the
FDG assay, it is easy to detect outer membrane peameabilization
by disappearance of fluorescein accumulation in DC cells, and
inner membrane peameabilization by increased fluorescence
especially in the medium of pump deletion mutants. Determina-
tion of efflux pump inhibition activity via the typical methods of
measuring the influx or efflux of some substrates by their
fluorescence with a plate reader makes it difficult to exclude the
effect of outer membrane peameabilizing activity. In addition,
accurate estimation of FDG hydrolysis through monitoring
fluorescence with a plate-reader is impractical because the total
fluorescence of fluorescein is higher when diffused in the medium
than when accumulated in the cells, and fluorescence determined
by a plate reader was usually higher in DB than in DC. Therefore,
fluorescence determined by a plate reader does not accurately
correlate with the amount of fluorescein produced, and it is
difficult to estimate the inhibitory effect on pumps with FDG by a
Figure 6. Effects of PAbN on FDG degradation determined by the microfluidic channel device. (A) Bright-field (top) and fluorescence
images (bottom) of the E. coli wild-type, DB, and DC cells treated with different concentrations of PAbN. (B) Distributions of the fluorescence
intensities of the cells and channels measured in the image shown in (A).
doi:10.1371/journal.pone.0018547.g006
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ination of pure efflux pump inhibition from membrane permea-
bilization. However, when more than two different pumps are
present in a cell, it may be difficult to detect the effect of a specific
inhibitor on either of them. To overcome this problem, we need a
mutant deleting all RND pumps and sustaining TolC in which
fluorescein is accumulated. Deletions of acrB, acrD, acrEF, mdtABC,
and mdtEF were not sufficient to ensure accumulation of
fluorescein in a manner similar to that in DC (data not shown).
D13-9001 is known to specifically inhibit the MexAB-OprM
pump [25]. In the microfluidic channel method, D13-9001 clearly
inhibited the MexAB-OprM pump but did not inhibit the
MexXY-OprM pump (Figure 7). The effect of D13-9001 on
AcrAB-TolC of E. coli would be detected by this method when a
strain producing only AcrAB-TolC is available. Combinatorial
effects of D13-9001 with the antimicrobials assessed by the
checkerboard method are easily understandable by the inhibition
of the AcrB or MexB pump in all the tested strains of E. coli and P.
aeruginosa. The synergy of D13-9001 was determined to be the
strongest with ATM, which is a substrate of MexB and not of other
pumps.
Throughout this study, we could not definitively answer the
question as to whether PAbN really acts on efflux pumps. We
observed that PAbN increased FDG hydrolysis and leakage of
fluorescein in all strains, especially in pump deletion mutants, by
this new method (Figure 6). Since PAbN was first reported, it has
been universally recognized as an efflux pump inhibitor [12,15],
and the effect of PAbN on MDRP S1 was remarkably synergistic
Figure 7. Effect of D13-9001 on MexAB-OprM and MexXY-OprM expressed in E. coli MG1655 DBC. (A) Bright-field (top) and fluorescence
images (bottom) of the DBC/pV, DBC/pABM, DBC/pXYM cells treated with different concentrations of D13-9001. (B) Distributions of the fluorescence
intensities of the cells and channels measured in the image shown in (A).
doi:10.1371/journal.pone.0018547.g007
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PAbN increased the susceptibilities of pump deletion mutants of
E. coli especially to ERY, although it had almost no effect on
CIP against E. coli expressing MexAB-OprM or MexXY-OprM
(Figure 4E), which means PAbN could not inhibit efflux of CIP by
MexB or MexY. PAbN also increased susceptibility of E. coli
expressing MexXY-OprM to ATM, which is not a substrate of
MexXY-OprM (Figure 4D). These actions of PAbN do not
correlate with efflux pumps, and are similar to those of outer
membrane permeabilizer PMBN. The effect of PAbN on the outer
membrane was already known when it was discovered [15]. They
used nitrocefin hydrolysis assay by intact cells to evaluate outer
membrane permeabilizing activity of PAbNi nP. aeruginosa, and
permeabilizing activity was visible in lower than 16 mg/ml on
outer membrane of a pump deficient strain or a CCCP applied
strain. Nitrocefin is a substrate of efflux pumps [38], so that
permeabilizing activity should be evaluated in pump deficient
condition. Permeabilizing activity of PAbN on outer membrane of
E. coli by the assay using nitrocefin (Figure 10) was comparable to
the activity obtained from the FDG assay and was higher than that
on outer membrane of P. aeruginosa [15]. Outer membrane
permeabilizing activity of PAbN have also been published by other
researchers using resazurin as a substrate [43]. In our FDG assay,
the effect of PAbN on the outer membrane of E. coli was visible in
4 mg/ml (Figure 6). LB was used for the FDG assay and the results
would be easy to compare with the results of synergy in MICs with
antimicrobial agents. LB used in our study contains 0.24 mM
Mg
2+ (information from the manufacturer). When additional
1m MM g
2+ was added to LB, effect of PAbN on outer membrane
decreased to some extent although it was not disappeared in the
FDG assay (data not shown), and accordingly, addition of Mg
2+ to
the medium also decreased synergistic activity of PAbN with ERY
to P. aeruginosa PAO1 (data not shown). Outer membrane
permeabilizing activity is known to increase the sensitivity of
Figure 8. Effect of PMBN on CIP, and ERY activity against E. coli and P. aeruginosa. Changes in CIP, and ERY MICs induced by PMBN were
determined by the checkerboard method.
doi:10.1371/journal.pone.0018547.g008
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intact outer membrane [32,44] as well as efflux pump inhibition,
and we could get similar results by PMBN. The effect of PAbNo n
antimicrobial agents (Figure 3–4) seems to be explainable with its
activity on membranes of E. coli. We could not obtain any clear
evidence of the inhibitory activity of PAbN on the efflux pump
itself. Although competitive inhibition of efflux pumps by another
substrate was not proved in E. coli by Elkins, et al. [45], the
possibility that PAbN competes with a substrate for binding to the
efflux pump cannot be excluded completely. Precise mechanism of
synergy between PAbN and antimicrobial agents should be
elucidated elsewhere.
Nevertheless, susceptibility-augmenting agents such as PAbN
may be useful in combination with a substrate of multi efflux
pumps such as ERY and CIP because it will be difficult to develop
a super inhibitor that can inhibit all pumps including those with
different structures. The effect of D13-9001 is simple and specific
to strains expressing AcrB or MexB pumps, and D13-9001 shows
the most synergistic effect with ATM, which is the substrate
preferred by MexB and no other pumps. From this new method, it
is concluded that D13-9001 specifically inhibits MexB, in contrast
Figure 9. Effects of agents on FDG degradation in DtolC
determined by the microfluidic channel device. (A) Fluorescence
images of the E. coli DC cells treated with different concentrations of PMBN
and PMB. (B) Distributions of the fluorescence intensities of the cells and
channels measured in the image shown in (A).
doi:10.1371/journal.pone.0018547.g009
Figure 10. Effect of PAbNo nn it r o ce f i nhy d r o ly s isb yi n t a c tce ll so f
wild-type E. coli MG1655 and its tolC deletion mutant. Both strains
were transformed with pMMB67HE before use. Exponentially growing cells
in LB containing 100 mg/ml of AMP were harvested and resuspended in
fresh LB for the assay. Nitrocefin hydrolysis was monitored by OD486 nm in a
384-well plate with a plate reader after exposure to PAbN for 10 min. (A)
shows results from Wild-type/pV, and (B) shows results from DC/pV.
doi:10.1371/journal.pone.0018547.g010
Figure 11. Effect of inhibitors on SYTOX Green uptake in E. coli
MG1655 and its pump deletion mutants. Exponentially growing
cells harvested in PBS containing 0.4% glucose were used. Membrane
integrity was determined by measuring SYTOX Green uptake after
exposure to D13-9001, PAbN, and PMB for 20 min. Fluorescence was
determined (Ex/Em: 504/523 nm) after an incubation of 10 min with
SYTOX Green in a black 384-well plate with a plate reader.
doi:10.1371/journal.pone.0018547.g011
Figure 12. Proposed mechanism of FDG hydrolysis and
transport in E. coli.
doi:10.1371/journal.pone.0018547.g012
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permeabilized the membranes of E. coli.
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